Zoneone Pharma develops next‑generation liposomal technologies and nanomedicines aimed at treating chronic disorders. By leveraging advanced lipid‑based delivery systems, the company creates targeted therapeutics that improve drug stability and bioavailability, enabling more effective treatment options for long‑term diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Many chronic diseases require drugs that have poor bioavailability, limited tissue targeting, and systemic side effects, leading to suboptimal therapeutic outcomes and patient adherence challenges.
Solution
Zoneonepharma creates advanced liposomal and nanomedicine platforms that encapsulate active pharmaceutical ingredients within lipid vesicles. This delivery approach protects drugs from degradation, improves solubility, and enables controlled release at the intended site of action. By enhancing target specificity and reducing off‑target exposure, the technology aims to increase efficacy while minimizing adverse effects for chronic disorder treatments. The platform is designed to be adaptable across a range of small molecules and biologics, facilitating the development of next‑generation therapeutics.
Target Audience
Primary customers are pharmaceutical companies and biotech firms developing therapies for chronic conditions that require improved delivery and safety profiles.
Features
- Proprietary liposomal formulation techniques that achieve high drug loading efficiency
- Surface modification options for active targeting to specific tissues or cell types
- Controlled-release mechanisms that sustain therapeutic levels over extended periods
- Scalable manufacturing processes compatible with GMP standards
- Integrated stability and safety profiling to support regulatory submissions